H
Hugo E. Vargas
Researcher at Mayo Clinic
Publications - 172
Citations - 6746
Hugo E. Vargas is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Liver transplantation & Cirrhosis. The author has an hindex of 41, co-authored 144 publications receiving 5776 citations.
Papers
More filters
Journal ArticleDOI
An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
Paul Y. Kwo,Parvez S. Mantry,Eoin Coakley,Helen S. Te,Hugo E. Vargas,Robert S. Brown,Fredric D. Gordon,Josh Levitsky,Norah A. Terrault,James R. Burton,Wangang Xie,Carolyn M. Setze,Prajakta S. Badri,Tami Pilot-Matias,Regis A. Vilchez,Xavier Forns +15 more
TL;DR: Treatment with the multitargeted regimen of ombitasvir-ABT-450/r and dasabuvir with ribavirin was associated with a low rate of serious adverse events and a high rate of sustained virologic response among liver-transplant recipients with recurrent HCV genotype 1 infection, a historically difficult-to-treat population.
Journal ArticleDOI
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Stefan Zeuzem,Graham R. Foster,Stanley Wang,Armen Asatryan,Edward Gane,Jordan J. Feld,Tarik Asselah,Marc Bourlière,Peter Ruane,Heiner Wedemeyer,Stanislas Pol,Robert Flisiak,Fred Poordad,Wan-Long Chuang,Catherine A.M. Stedman,Steven L. Flamm,Paul Y. Kwo,Gregory J. Dore,Gladys Sepulveda-Arzola,Stuart K. Roberts,Ruth Soto-Malave,Kelly Kaita,Massimo Puoti,John M. Vierling,Edward Tam,Hugo E. Vargas,Rafi Bruck,Francisco Fuster,Seung-Woon Paik,Franco Felizarta,Jens Kort,Bo Fu,Ran Liu,Teresa I. Ng,Tami Pilot-Matias,Chih-Wei Lin,Roger Trinh,Federico J. Mensa +37 more
TL;DR: Once‐daily treatment with glecaprevir–pibrentasvir for either 8 weeks or 12 weeks achieved high rates of sustained virologic response among patients with HCV genotype 1 or 3 infection who did not have cirrhosis.
Journal ArticleDOI
Search for Hepatitis C Virus Negative-Strand RNA Sequences and Analysis of Viral Sequences in the Central Nervous System: Evidence of Replication
Marek Radkowski,Jeffrey Wilkinson,Marek Nowicki,Debra Adair,Hugo E. Vargas,Craig Ingui,Jorge Rakela,Tomasz Laskus +7 more
TL;DR: The results of the present study suggest that HCV can replicate in the central nervous system, probably in cells of the macrophage/monocyte lineage.
Journal ArticleDOI
Six‐minute walk distance predicts mortality in liver transplant candidates
Elizabeth J. Carey,D. Eric Steidley,Bashar Aqel,Thomas J. Byrne,Kristin L. Mekeel,Jorge Rakela,Hugo E. Vargas,David D. Douglas +7 more
TL;DR: The 6MWD is significantly reduced in patients awaiting LT and is inversely correlated with the native MELD score, which is commonly used to predict mortality in patients with cardiac and pulmonary diseases.
Journal ArticleDOI
Liver transplantation for hepatocellular carcinoma: the MELD impact.
Pratima Sharma,Vijayan Balan,Jose L. Hernandez,Ann M. Harper,Erick B. Edwards,Hector Rodriguez-Luna,Thomas J. Byrne,Hugo E. Vargas,David C. Mulligan,Jorge Rakela,Russell H. Wiesner +10 more
TL;DR: The new allocation policy of the United Network of Organ Sharing based on the model for end‐stage liver disease (MELD) gives candidates with stage T1 or stage T2 hepatocellular carcinoma (HCC) a priority MELD score beyond their degree of hepatic decompensation, leading to an increased incidence rate of DDLT in HCC candidates.